As­traZeneca grabs PhI­II AT­TR drug from Io­n­is — in­fus­ing $200M cash in­to strug­gling part­ner

As­traZeneca is pluck­ing an­oth­er an­ti­sense drug out of Io­n­is’ pro­lif­ic pipeline.

Pay­ing $200 mil­lion in cash, As­traZeneca has inked a de­vel­op­ment and com­mer­cial­iza­tion deal around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER